Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 143

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 143
---
     | $         |     | $          |
| Underwriting discounts and commissions to be paid to underwriters by us |     | $           |     | $                       |     | $         |     | $          |
| Proceeds, before expenses, to us                                        |     | $           |     | $                       |     | $         |     | $          |

We have agreed
to pay underwriter’s out-of-pocket accountable expenses, actually incurred, including underwriter’s legal fees, up to a maximum
amount of $ if this offering is completed and up to $ if
this offering is not completed.

We estimate that
the total expenses of the offering payable by us, not including the underwriting discounts and commissions, will be approximately $ .
This amount includes the underwriter’s expenses described above.

Underwriter Warrants

We have also agreed
to issue to (or its permitted assignees) Underwriter Warrants
entitling it to purchase a number of Depositary Shares equal to % of the units sold in this offering. The Underwriter
Warrants are identical to the Series L Warrants.

| 77 |

Right of First Refusal

We have agreed
to grant the underwriter, for the -month period following the effective date of the registration statement related to
this offering, a right of first refusal to act as managing underwriter and book runner, placement agent, or sales agent, for any and all
future public or private equity, equity-linked or debt (excluding commercial bank debt or the exercise of existing warrants) offerings
for which the Company retains the service of an underwriter, placement agent, or sales agent in connection with such offering. In accordance
with FINRA Rule 5110(g)(6), such right of first refusal shall not have a duration of more than three years from the commencement of sales
of this offering.

Tail Financing Payments

Upon closing of
this offering, or if we terminate our engagement agreement with , other than for cause, then upon such termination,
we subsequently complete any public or private financing any time during the ( ) months after such termination with
any investors contacted or introduced to the Company by , then
shall be entitled to receive the same compensation for such offering as it would have been entitled to in connection with this offering.

Lock-Up Agreements

We and each of
our officers and directors have agreed, subject to certain exceptions, not to offer, issue, sell, contract to sell, encumber for the sale
of or otherwise dispose of